[Contribution of immunotyping in the diagnosis and in the prognosis of acute leukemia].
Characterisation of acute leukaemia has greatly progressed due to the discovery of a large number of molecules using monoclonal antibody techniques. In acute lymphoblastic leukaemia, these techniques not only demonstrate the lymphoid origin of the proliferation but also allow to distinguish between T and B lymphoblasts at various stages of differentiation. This information is useful in establishing prognosis and making therapeutic choices. In acute myeloid leukaemia, immunologic phenotyping confirms the French-American-British (FAB) classification, allowing diagnosis of undifferentiated acute myeloid leukaemia (LAM 0) and can itself constitute a prognostic element.
Merle-Béral
H
H
I. Service d'hématologie, Groupe hospitalier Pitié-Salpêtrière, Paris.
Boucheix
C
C
D000208:Acute Disease; D001402:B-Lymphocytes / Q000473:pathology; D006801:Humans; D016130:Immunophenotyping; D007951:Leukemia, Myeloid / Q000145:classification / Q000175:diagnosis* / Q000276:immunology / Q000473:pathology; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000175:diagnosis* / Q000276:immunology / Q000473:pathology; D011379:Prognosis; D013601:T-Lymphocytes / Q000473:pathology